China's Ant Group posted a 91% fall in net profit to 1.2 billion yuan in the three months to Sep 30, according to ...
Blue Owl Capital demonstrates robust operating performance, with AUM surpassing $300 billion and management fees growing YoY ...
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results